Bausch Health Companies Inc (BHC) concluded trading on Thursady at a closing price of $9.30, with 8.04 million shares of worth about $74.74 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 12.73% during that period and on Thursady the price saw a gain of about 7.27%. Currently the company’s common shares owned by public are about 361.90M shares, out of which, 356.87M shares are available for trading.
However, the stock later moved at a day high price of 9.48, or with a gain of 7.27%. Stock saw a price change of 10.32% in past 5 days and over the past one month there was a price change of 13.41%. Year-to-date (YTD), BHC shares are showing a performance of 15.96% which increased to 4.97% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $5.57 but also hit the highest price of $10.23 during that period. The average intraday trading volume for Bausch Health Companies Inc shares is 2.00 million. The stock is currently trading 13.12% above its 20-day simple moving average (SMA20), while that difference is up 16.28% for SMA50 and it goes to 17.98% higher than SMA200.
Bausch Health Companies Inc (NYSE: BHC) currently have 361.90M outstanding shares and institutions hold larger chunk of about 79.17% of that.
The stock has a current market capitalization of $3.40B and its 3Y-monthly beta is at 0.80. It has posted earnings per share of -$2.65 in the same period. It has Quick Ratio of 0.89. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for BHC, volatility over the week remained 3.91% while standing at 3.33% over the month.
Analysts are in expectations that Bausch Health Companies Inc (BHC) stock would likely to be making an EPS of $1.02 in the current quarter, while forecast for next quarter EPS is $0.7 and it is $3.81 for next year. For the current quarter EPS, analysts have given the company a lowest target $0.99 which is $1.11 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of $1.03 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 12.33% while it is estimated to increase by 4.56% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Jefferies on September 20, 2023 offering a Buy rating for the stock and assigned a target price range of between $9 and $16 to it. On July 29, 2022, Truist Downgrade their recommendations, while on July 29, 2022, RBC Capital Mkts Downgrade their ratings for the stock with a price target of $5. Stock get a Neutral rating from JP Morgan on July 28, 2022.
